Lumos Pharma, Inc. (LUMO)
NASDAQ: LUMO · Real-Time Price · USD
4.370
-0.080 (-1.80%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Lumos Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Lumos Pharma stock have an average target of 9.38, with a low estimate of 4.25 and a high estimate of 16. The average target predicts an increase of 114.65% from the current stock price of 4.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lumos Pharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $28 → $4.25 | Strong Buy → Hold | Downgrades | $28 → $4.25 | -2.75% | Oct 24, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades $20 → $4.25 | Strong Buy → Hold | Downgrades | $20 → $4.25 | -2.75% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +540.73% | Sep 27, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +266.13% | Sep 24, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $16 → $13 | Buy | Maintains | $16 → $13 | +197.48% | Aug 2, 2024 |
Financial Forecast
Revenue This Year
5.74M
from 2.05M
Increased by 179.77%
Revenue Next Year
306.00K
from 5.74M
Decreased by -94.67%
EPS This Year
-3.65
from -4.18
EPS Next Year
-2.23
from -3.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.3M | 1.3M | 45.4M | ||
| Avg | 5.7M | 306,000 | 14.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 985.3% | -78.0% | 14,734.0% | ||
| Avg | 179.8% | -94.7% | 4,703.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.43 | -1.18 | -0.74 | ||
| Avg | -3.65 | -2.23 | -1.12 | ||
| Low | -3.80 | -3.86 | -1.30 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.